Nematode Cancer Test ”N-NOSE”

At HIROTSU BIO SCIENCE, we aim for the practical application of the world’s most advanced nematode behavior analysis technology as a cancer screening test, “N-NOSE,” which is capable of identifying trace odors in urine samples that indicate the presence of cancer.

This N-NOSE cancer test is based on the analysis of chemotaxis response of nematodes, which are attracted to the odor of urine samples of cancer patients, and avoid the urine of healthy subjects.
In addition to being a simple and affordable screening method, it is capable of detecting various types of cancer, and in the latest clinical study showed approximately 90% sensitivity, which indicates a high level of precision for early cancer detection.
Practical implementation is scheduled to begin in January 2020, with an expected screening fee of several thousand yen.

Types of cancer known to cause response in nematodes (as of September 2018):

18 cancers including stomach cancer, colorectal cancer, lung cancer, breast cancer, uterine cancer, pancreatic cancer, liver cancer, prostate cancer, esophageal cancer, ovarian cancer, bile duct cancer, gall bladder cancer, appendix cancer, kidney cancer, and bladder cancer.

①Painless Only 1 drop of urine necessary for analysis.
②Simple As there are no special conditions related to collecting the urine sample (i.e. fasting), a sample provided during a normal health check is sufficient.
③Fast Receive test results in approximately 1 hour.
④Affordable Inexpensive cost of the testing system enables adoption in developing countries
⑤Cancer screening Capable of detecting all 18 cancer types studied so far, including pancreatic cancer, which has been difficult to detect early.
⑥Early detection High sensitivity to Stage 0 and Stage 1 cancers.
⑦High sensitivity Approximately 90% accuracy

If N-NOSE is implemented for the public, it is expected to lead to an increase in the consultation rate for cancer, as well as a reduction in the number of cancer-related deaths and decreased cost of medical expenses as cancer can be detected at an early stage. We will continue to work towards practical implementation as soon as possible, as well as pursue research for further technological development.